InspireMD | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 2.523 M

LB filings
2025.11.10 21:12
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 2.523 M, beating the estimate of USD 1.76 M.

EPS: As of FY2025 Q3, the actual value is USD -0.17.

EBIT: As of FY2025 Q3, the actual value is USD -13.05 M.

Segment Revenue

  • Total Revenue: $2,523,000 for the three months ended September 30, 2025, compared to $1,810,000 for the same period in 2024, representing a 39.4% increase.
  • Total Revenue: $5,830,000 for the nine months ended September 30, 2025, compared to $5,060,000 for the same period in 2024, representing a 15.2% increase.

Operational Metrics

  • Gross Profit: $864,000 for the three months ended September 30, 2025, compared to $414,000 for the same period in 2024, representing a 108.7% increase.
  • Gross Profit: $1,469,000 for the nine months ended September 30, 2025, compared to $1,037,000 for the same period in 2024, representing a 41.7% increase.
  • Net Loss: -$12,708,000 for the three months ended September 30, 2025, compared to -$7,890,000 for the same period in 2024.
  • Net Loss: -$37,025,000 for the nine months ended September 30, 2025, compared to -$22,831,000 for the same period in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: -$25,758,000 for the nine months ended September 30, 2025, compared to -$15,118,000 for the same period in 2024.
  • Net Cash Provided by Investing Activities: $14,575,000 for the nine months ended September 30, 2025, compared to $4,399,000 for the same period in 2024.
  • Net Cash Provided by Financing Activities: $55,569,000 for the nine months ended September 30, 2025, compared to $16,889,000 for the same period in 2024.

Unique Metrics

  • Gross Margin: Increased to 34.2% during the three months ended September 30, 2025, from 22.9% during the same period in 2024.
  • Gross Margin: Increased to 25.2% for the nine months ended September 30, 2025, from 20.5% for the same period in 2024.

Future Outlook and Strategy

  • Core Business Focus: InspireMD, Inc. plans to continue the commercialization of its products and raise capital through the sale of additional equity securities, debt, or capital inflows from strategic partnerships and exercise of warrants.
  • Non-Core Business: The company is developing a new transcarotid artery revascularization (TCAR) system, SwitchGuard™ neuroprotection system, for transcarotid access and neuro protection, and intends to explore new indications for CGuard to leverage the advantages of stent design and mesh protection.
  • Priority: The company aims to establish the CGuard Carotid Stent System as a viable alternative to vascular surgery, estimating the addressable market to be approximately $1.3 billion, with potential growth to $9.3 billion.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.